High Cell Death Rates at Start of Ibrutinib Therapy Predict for Deeper Remissions in Patients with Chronic Lymphocytic Leukemia (CLL)

被引：0
|
作者：
Kim, Ekaterina [1 ]
Sivina, Mariela [1 ]
Vaca, Alicia [1 ]
Ferrajoli, Alessandra [1 ]
Jain, Nitin [2 ]
Thompson, Philip A. [1 ]
Wierda, William G. [1 ]
Wodarz, Dominik [3 ]
Chiorazzi, Nicholas [4 ]
Burger, Jan A. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[2] MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
[3] Univ Calif Irvine, Irvine, CA USA
[4] Feinstein Inst Med Res, Karches Ctr Oncol Res, Manhasset, NY USA
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-160238
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：4140 / 4141
页数：2
相关论文
共 50 条
  • [21] Combined Ibrutinib and Venetoclax in Patients with Treatment-Naive High-Risk Chronic Lymphocytic Leukemia (CLL)
    Jain, Nitin
    Keating, Michael J.
    Thompson, Philip A.
    Ferrajoli, Alessandra
    Burger, Jan A.
    Borthakur, Gautam
    Takahashi, Koichi
    Estrov, Zeev E.
    Fowler, Nathan H.
    Kadia, Tapan M.
    Konopleva, Marina Y.
    Alvarado, Yesid
    Yilmaz, Musa
    DiNardo, Courtney D.
    Bose, Prithviraj
    Ohanian, Maro N.
    Pemmaraju, Naveen
    Jabbour, Elias J.
    Sasaki, Koji
    Kanagal-Shamanna, Rashmi
    Patel, Keyur
    Jorgensen, Jeffrey L.
    Garg, Naveen
    Wang, Xuemei
    Sondermann, Katrina
    Cruz, Nichole
    Wei, Chongjuan
    Ayala, Ana
    Plunkett, William
    Kantarjian, Hagop M.
    Gandhi, Varsha
    Wierda, William G.
    BLOOD, 2018, 132
  • [22] The Importance of Pharmacovigilance during Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL) in Routine Clinical Practice
    Finnes, Heidi D.
    Chaffee, Kari G.
    Call, Timothy G.
    Ding, Wei
    Bowen, Deborah A.
    Conte, Michael
    McCullough, Kristen B.
    Merten, Julianna A.
    Bartoo, Gabriel T.
    Smith, Matthew D.
    Schwager, Susan M.
    Slager, Susan L.
    Kay, Neil E.
    Shanafelt, Tait D.
    Parikh, Sameer A.
    BLOOD, 2015, 126 (23)
  • [23] Secondary Hypogammaglobulinemia in Patients with Chronic Lymphocytic Leukemia Receiving Ibrutinib Therapy
    Serhat Çelik
    Leylagül Kaynar
    Zeynep Tuğba Güven
    Mustafa Baydar
    Muzaffer Keklik
    Mustafa Çetin
    Ali Ünal
    Fatih Demirkan
    Indian Journal of Hematology and Blood Transfusion, 2022, 38 : 282 - 289
  • [24] Safe Start of Ibrutinib in Patients with Chronic Lymphocytic Leukemia and Uncontrolled Autoimmune Hemolytic Anemia
    Garcia-Horton, Alejandro
    St Bernard, Rosanne
    Lazo-Langner, Alejandro
    Xenocostas, Anargyros
    Mangel, Joy
    Howson-Jan, Kang
    Lam, Selay
    Hsia, Cyrus C.
    BLOOD, 2018, 132
  • [25] Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia
    Maddocks, Kami J.
    Ruppert, Amy S.
    Lozanski, Gerard
    Heerema, Nyla A.
    Zhao, Weiqiang
    Abruzzo, Lynne
    Lozanski, Arletta
    Davis, Melanie
    Gordon, Amber
    Smith, Lisa L.
    Mantel, Rose
    Jones, Jeffrey A.
    Flynn, Joseph M.
    Jaglowski, Samantha M.
    Andritsos, Leslie A.
    Awan, Farrukh
    Blum, Kristie A.
    Grever, Michael R.
    Johnson, Amy J.
    Byrd, John C.
    Woyach, Jennifer A.
    JAMA ONCOLOGY, 2015, 1 (01) : 80 - 87
  • [26] Secondary Hypogammaglobulinemia in Patients with Chronic Lymphocytic Leukemia Receiving Ibrutinib Therapy
    celik, Serhat
    Kaynar, Leylagul
    Guven, Zeynep Tugba
    Baydar, Mustafa
    Keklik, Muzaffer
    cetin, Mustafa
    Unal, Ali
    Demirkan, Fatih
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2022, 38 (02) : 282 - 289
  • [27] Activity and Tolerability of Ibrutinib in Combination With Ofatumumab in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
    Jaglowski, Samantha M.
    Jones, Jeffrey A.
    Flynn, Joseph M.
    Andritsos, Leslie A.
    Maddocks, Kami J.
    Woyach, Jennifer A.
    Blum, Kristie A.
    Greyer, Michael R.
    Geyer, Susan Michelle
    Heerema, Nyla A.
    Lozanski, Gerard
    Stefanos, Mona
    Hall, Nathan
    Nagar, Veena
    Munneke, Brian
    West, Jamie-Sue
    Neuenburg, Jutta K.
    James, Danelle F.
    Johnson, Amy J.
    Byrd, John C.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 : S206 - S207
  • [28] DECREASED EXPRESSION OF ADHESION MOLECULES IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) CELLS OF PATIENTS TREATED WITH IBRUTINIB
    Guarini, A.
    De Propris, M. S.
    Milani, M. L.
    Intoppa, S.
    Faraone, S.
    Peragine, N.
    Mariglia, P.
    Puzzolo, M. C.
    Mauro, F. R.
    Del Giudice, I.
    Foa, R.
    HAEMATOLOGICA, 2017, 102 : 406 - 406
  • [29] Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)
    Jain, Nitin
    Keating, Michael J.
    Thompson, Philip A.
    Ferrajoli, Alessandra
    Burger, Jan A.
    Borthakur, Gautam M.
    Takahashi, Koichi
    Estrov, Zeev E.
    Fowler, Nathan H.
    Kadia, Tapan M.
    Konopleva, Marina Y.
    Alvarado, Yesid
    Yilmaz, Musa
    DiNardo, Courtney D.
    Bose, Prithviraj
    Ohanian, Maro
    Pemmaraju, Naveen
    Jabbour, Elias
    Sasaki, Koji
    Kanagal-Shamanna, Rashmi
    Patel, Keyur
    Jorgensen, Jeffrey L.
    Wang, Sa A.
    Garg, Naveen
    Wang, Xuemei
    Sondermann, Katrina
    Cruz, Nichole
    Wei, Chongjuan
    Ayala, Ana
    Plunkett, William
    Kantarjian, Hagop M.
    Gandhi, Varsha
    Wierda, William G.
    BLOOD, 2019, 134
  • [30] HYPOGAMMAGLOBULINEMIA AND INFECTIONS IN IBRUTINIB-TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS: A PROSPECTIVE STUDY
    Cassin, R.
    Noto, A.
    Silvestris, I.
    Barbieri, M.
    Cappello, E.
    Lonati, S.
    Baldini, L.
    Neri, A.
    Reda, G.
    HAEMATOLOGICA, 2019, 104 : 38 - 38
12345